世界の乳幼児用混合ワクチン市場予測2023-2029:5種混合ワクチン、4種混合ワクチン、3種混合ワクチン、その他

• 英文タイトル:Infant and Child Multiple Vaccine Market, Global Outlook and Forecast 2023-2029

Infant and Child Multiple Vaccine Market, Global Outlook and Forecast 2023-2029「世界の乳幼児用混合ワクチン市場予測2023-2029:5種混合ワクチン、4種混合ワクチン、3種混合ワクチン、その他」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2312MG02111
• 出版社/出版日:Market Monitor Global / 2023年12月
• レポート形態:英文、PDF、99ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医薬品
• 販売価格(消費税別)
  Single User¥487,500 (USD3,250)▷ お問い合わせ
  Multi User¥633,750 (USD4,225)▷ お問い合わせ
  Enterprise User¥731,250 (USD4,875)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Global Infant and Child Multiple Vaccine Market 調査レポートは次の情報を含め、グローバルにおけるの乳幼児用混合ワクチン市場規模と予測を収録しています。
・世界の乳幼児用混合ワクチン市場:売上、2018年-2023年、2024年-2029年
・世界の乳幼児用混合ワクチン市場:販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の乳幼児用混合ワクチン市場は2022年に000Mドルと評価され、予測期間中に000%のCAGRで2029年までに000Mドルに達すると予測されています。アメリカ市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「5種混合ワクチン」セグメントは今後6年間、000%の年平均成長率で2029年までに000Mドルに成長すると予測されています。

乳幼児用混合ワクチンのグローバル主要企業は、Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnologyなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

マーケットモニターグローバル社は、乳幼児用混合ワクチンのメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別マーケット分析】

世界の乳幼児用混合ワクチン市場:タイプ別、2018年-2023年、2024年-2029年
世界の乳幼児用混合ワクチン市場:タイプ別市場シェア、2022年
・5種混合ワクチン、4種混合ワクチン、3種混合ワクチン、その他

世界の乳幼児用混合ワクチン市場:用途別、2018年-2023年、2024年-2029年
世界の乳幼児用混合ワクチン市場:用途別市場シェア、2022年
・12ヶ月以下、12ヶ月以上

世界の乳幼児用混合ワクチン市場:地域・国別、2018年-2023年、2024年-2029年
世界の乳幼児用混合ワクチン市場:地域別市場シェア、2022年
・北米:アメリカ、カナダ、メキシコ
・ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
・アジア:中国、日本、韓国、東南アジア、インド
・南米:ブラジル、アルゼンチン
・中東・アフリカ:トルコ、イスラエル、サウジアラビア、UAE

【競争分析】

また、当レポートは主要な参入企業の分析を提供します。
・主要企業における乳幼児用混合ワクチンのグローバル売上、2018年-2023年
・主要企業における乳幼児用混合ワクチンのグローバル売上シェア、2022年
・主要企業における乳幼児用混合ワクチンのグローバル販売量、2018年-2023年
・主要企業における乳幼児用混合ワクチンのグローバル販売量シェア、2022年

さらに、当レポートは主要企業の情報を提示します。
Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnology

*************************************************************

・調査・分析レポートの概要
乳幼児用混合ワクチン市場の定義
市場セグメント
世界の乳幼児用混合ワクチン市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の乳幼児用混合ワクチン市場規模
世界の乳幼児用混合ワクチン市場規模:2022年 VS 2029年
世界の乳幼児用混合ワクチン市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの乳幼児用混合ワクチンの売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の乳幼児用混合ワクチン製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分:5種混合ワクチン、4種混合ワクチン、3種混合ワクチン、その他
乳幼児用混合ワクチンのタイプ別グローバル売上・予測

・用途別市場分析
用途区分:12ヶ月以下、12ヶ月以上
乳幼児用混合ワクチンの用途別グローバル売上・予測

・地域別市場分析
地域別乳幼児用混合ワクチン市場規模 2022年と2029年
地域別乳幼児用混合ワクチン売上・予測
北米市場:アメリカ、カナダ、メキシコ
ヨーロッパ市場:ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場:中国、日本、韓国、東南アジア、インド
南米市場:ブラジル、アルゼンチン
中東・アフリカ市場:トルコ、イスラエル、サウジアラビア、UAE

・主要企業の情報(企業概要、事業概要、主要製品、売上、ニュースなど)
Sanofi、 GSK、 Mitsubishi Tanabe Pharma、 KM Biologics、 Wuhan Institute of Biological Products、 Walvax Biotechnology、 Chengdu Institute of Biological Products、 Minhai Biotechnology
...

This research report provides a comprehensive analysis of the Infant and Child Multiple Vaccine market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Infant and Child Multiple Vaccine market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Infant and Child Multiple Vaccine, challenges faced by the industry, and potential opportunities for market players.
The global Infant and Child Multiple Vaccine market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Infant and Child Multiple Vaccine market presents opportunities for various stakeholders, including 12 Months Below, 12 Months Above. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Infant and Child Multiple Vaccine market. Additionally, the growing consumer demand present avenues for market expansion.
The global Infant and Child Multiple Vaccine market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The process of upgrading global multi-vaccine products is a process of solidifying the competitive landscape.
Key Features:
The research report on the Infant and Child Multiple Vaccine market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Infant and Child Multiple Vaccine market.
Market Overview: The report provides a comprehensive overview of the Infant and Child Multiple Vaccine market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Pentavalent Vaccine, Quadruple Vaccine), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Infant and Child Multiple Vaccine market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Infant and Child Multiple Vaccine market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Infant and Child Multiple Vaccine market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Infant and Child Multiple Vaccine market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Infant and Child Multiple Vaccine market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Infant and Child Multiple Vaccine market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Infant and Child Multiple Vaccine, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Infant and Child Multiple Vaccine market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Infant and Child Multiple Vaccine market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value.
Market segment by Type
Pentavalent Vaccine
Quadruple Vaccine
Triple Vaccine
Others
Market segment by Application
12 Months Below
12 Months Above
Global Infant and Child Multiple Vaccine Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Sanofi
GSK
Mitsubishi Tanabe Pharma
KM Biologics
Wuhan Institute of Biological Products
Walvax Biotechnology
Chengdu Institute of Biological Products
Minhai Biotechnology
Outline of Major Chapters:
Chapter 1: Introduces the definition of Infant and Child Multiple Vaccine, market overview.
Chapter 2: Global Infant and Child Multiple Vaccine market size in revenue and volume.
Chapter 3: Detailed analysis of Infant and Child Multiple Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Infant and Child Multiple Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: Global Infant and Child Multiple Vaccine capacity by region & country.
Chapter 9: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 10: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 11: The main points and conclusions of the report.

レポート目次

1 Introduction to Research & Analysis Reports
1.1 Infant and Child Multiple Vaccine Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Infant and Child Multiple Vaccine Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Infant and Child Multiple Vaccine Overall Market Size
2.1 Global Infant and Child Multiple Vaccine Market Size: 2022 VS 2029
2.2 Global Infant and Child Multiple Vaccine Revenue, Prospects & Forecasts: 2018-2029
2.3 Global Infant and Child Multiple Vaccine Sales: 2018-2029
3 Company Landscape
3.1 Top Infant and Child Multiple Vaccine Players in Global Market
3.2 Top Global Infant and Child Multiple Vaccine Companies Ranked by Revenue
3.3 Global Infant and Child Multiple Vaccine Revenue by Companies
3.4 Global Infant and Child Multiple Vaccine Sales by Companies
3.5 Global Infant and Child Multiple Vaccine Price by Manufacturer (2018-2023)
3.6 Top 3 and Top 5 Infant and Child Multiple Vaccine Companies in Global Market, by Revenue in 2022
3.7 Global Manufacturers Infant and Child Multiple Vaccine Product Type
3.8 Tier 1, Tier 2 and Tier 3 Infant and Child Multiple Vaccine Players in Global Market
3.8.1 List of Global Tier 1 Infant and Child Multiple Vaccine Companies
3.8.2 List of Global Tier 2 and Tier 3 Infant and Child Multiple Vaccine Companies
4 Sights by Product
4.1 Overview
4.1.1 By Type – Global Infant and Child Multiple Vaccine Market Size Markets, 2022 & 2029
4.1.2 Pentavalent Vaccine
4.1.3 Quadruple Vaccine
4.1.4 Triple Vaccine
4.1.5 Others
4.2 By Type – Global Infant and Child Multiple Vaccine Revenue & Forecasts
4.2.1 By Type – Global Infant and Child Multiple Vaccine Revenue, 2018-2023
4.2.2 By Type – Global Infant and Child Multiple Vaccine Revenue, 2024-2029
4.2.3 By Type – Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
4.3 By Type – Global Infant and Child Multiple Vaccine Sales & Forecasts
4.3.1 By Type – Global Infant and Child Multiple Vaccine Sales, 2018-2023
4.3.2 By Type – Global Infant and Child Multiple Vaccine Sales, 2024-2029
4.3.3 By Type – Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
4.4 By Type – Global Infant and Child Multiple Vaccine Price (Manufacturers Selling Prices), 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Infant and Child Multiple Vaccine Market Size, 2022 & 2029
5.1.2 12 Months Below
5.1.3 12 Months Above
5.2 By Application – Global Infant and Child Multiple Vaccine Revenue & Forecasts
5.2.1 By Application – Global Infant and Child Multiple Vaccine Revenue, 2018-2023
5.2.2 By Application – Global Infant and Child Multiple Vaccine Revenue, 2024-2029
5.2.3 By Application – Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
5.3 By Application – Global Infant and Child Multiple Vaccine Sales & Forecasts
5.3.1 By Application – Global Infant and Child Multiple Vaccine Sales, 2018-2023
5.3.2 By Application – Global Infant and Child Multiple Vaccine Sales, 2024-2029
5.3.3 By Application – Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
5.4 By Application – Global Infant and Child Multiple Vaccine Price (Manufacturers Selling Prices), 2018-2029
6 Sights by Region
6.1 By Region – Global Infant and Child Multiple Vaccine Market Size, 2022 & 2029
6.2 By Region – Global Infant and Child Multiple Vaccine Revenue & Forecasts
6.2.1 By Region – Global Infant and Child Multiple Vaccine Revenue, 2018-2023
6.2.2 By Region – Global Infant and Child Multiple Vaccine Revenue, 2024-2029
6.2.3 By Region – Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
6.3 By Region – Global Infant and Child Multiple Vaccine Sales & Forecasts
6.3.1 By Region – Global Infant and Child Multiple Vaccine Sales, 2018-2023
6.3.2 By Region – Global Infant and Child Multiple Vaccine Sales, 2024-2029
6.3.3 By Region – Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
6.4 North America
6.4.1 By Country – North America Infant and Child Multiple Vaccine Revenue, 2018-2029
6.4.2 By Country – North America Infant and Child Multiple Vaccine Sales, 2018-2029
6.4.3 US Infant and Child Multiple Vaccine Market Size, 2018-2029
6.4.4 Canada Infant and Child Multiple Vaccine Market Size, 2018-2029
6.4.5 Mexico Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5 Europe
6.5.1 By Country – Europe Infant and Child Multiple Vaccine Revenue, 2018-2029
6.5.2 By Country – Europe Infant and Child Multiple Vaccine Sales, 2018-2029
6.5.3 Germany Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.4 France Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.5 U.K. Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.6 Italy Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.7 Russia Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.8 Nordic Countries Infant and Child Multiple Vaccine Market Size, 2018-2029
6.5.9 Benelux Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6 Asia
6.6.1 By Region – Asia Infant and Child Multiple Vaccine Revenue, 2018-2029
6.6.2 By Region – Asia Infant and Child Multiple Vaccine Sales, 2018-2029
6.6.3 China Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6.4 Japan Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6.5 South Korea Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6.6 Southeast Asia Infant and Child Multiple Vaccine Market Size, 2018-2029
6.6.7 India Infant and Child Multiple Vaccine Market Size, 2018-2029
6.7 South America
6.7.1 By Country – South America Infant and Child Multiple Vaccine Revenue, 2018-2029
6.7.2 By Country – South America Infant and Child Multiple Vaccine Sales, 2018-2029
6.7.3 Brazil Infant and Child Multiple Vaccine Market Size, 2018-2029
6.7.4 Argentina Infant and Child Multiple Vaccine Market Size, 2018-2029
6.8 Middle East & Africa
6.8.1 By Country – Middle East & Africa Infant and Child Multiple Vaccine Revenue, 2018-2029
6.8.2 By Country – Middle East & Africa Infant and Child Multiple Vaccine Sales, 2018-2029
6.8.3 Turkey Infant and Child Multiple Vaccine Market Size, 2018-2029
6.8.4 Israel Infant and Child Multiple Vaccine Market Size, 2018-2029
6.8.5 Saudi Arabia Infant and Child Multiple Vaccine Market Size, 2018-2029
6.8.6 UAE Infant and Child Multiple Vaccine Market Size, 2018-2029
7 Manufacturers & Brands Profiles
7.1 Sanofi
7.1.1 Sanofi Company Summary
7.1.2 Sanofi Business Overview
7.1.3 Sanofi Infant and Child Multiple Vaccine Major Product Offerings
7.1.4 Sanofi Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.1.5 Sanofi Key News & Latest Developments
7.2 GSK
7.2.1 GSK Company Summary
7.2.2 GSK Business Overview
7.2.3 GSK Infant and Child Multiple Vaccine Major Product Offerings
7.2.4 GSK Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.2.5 GSK Key News & Latest Developments
7.3 Mitsubishi Tanabe Pharma
7.3.1 Mitsubishi Tanabe Pharma Company Summary
7.3.2 Mitsubishi Tanabe Pharma Business Overview
7.3.3 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Major Product Offerings
7.3.4 Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.3.5 Mitsubishi Tanabe Pharma Key News & Latest Developments
7.4 KM Biologics
7.4.1 KM Biologics Company Summary
7.4.2 KM Biologics Business Overview
7.4.3 KM Biologics Infant and Child Multiple Vaccine Major Product Offerings
7.4.4 KM Biologics Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.4.5 KM Biologics Key News & Latest Developments
7.5 Wuhan Institute of Biological Products
7.5.1 Wuhan Institute of Biological Products Company Summary
7.5.2 Wuhan Institute of Biological Products Business Overview
7.5.3 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Major Product Offerings
7.5.4 Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.5.5 Wuhan Institute of Biological Products Key News & Latest Developments
7.6 Walvax Biotechnology
7.6.1 Walvax Biotechnology Company Summary
7.6.2 Walvax Biotechnology Business Overview
7.6.3 Walvax Biotechnology Infant and Child Multiple Vaccine Major Product Offerings
7.6.4 Walvax Biotechnology Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.6.5 Walvax Biotechnology Key News & Latest Developments
7.7 Chengdu Institute of Biological Products
7.7.1 Chengdu Institute of Biological Products Company Summary
7.7.2 Chengdu Institute of Biological Products Business Overview
7.7.3 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Major Product Offerings
7.7.4 Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.7.5 Chengdu Institute of Biological Products Key News & Latest Developments
7.8 Minhai Biotechnology
7.8.1 Minhai Biotechnology Company Summary
7.8.2 Minhai Biotechnology Business Overview
7.8.3 Minhai Biotechnology Infant and Child Multiple Vaccine Major Product Offerings
7.8.4 Minhai Biotechnology Infant and Child Multiple Vaccine Sales and Revenue in Global (2018-2023)
7.8.5 Minhai Biotechnology Key News & Latest Developments
8 Global Infant and Child Multiple Vaccine Production Capacity, Analysis
8.1 Global Infant and Child Multiple Vaccine Production Capacity, 2018-2029
8.2 Infant and Child Multiple Vaccine Production Capacity of Key Manufacturers in Global Market
8.3 Global Infant and Child Multiple Vaccine Production by Region
9 Key Market Trends, Opportunity, Drivers and Restraints
9.1 Market Opportunities & Trends
9.2 Market Drivers
9.3 Market Restraints
10 Infant and Child Multiple Vaccine Supply Chain Analysis
10.1 Infant and Child Multiple Vaccine Industry Value Chain
10.2 Infant and Child Multiple Vaccine Upstream Market
10.3 Infant and Child Multiple Vaccine Downstream and Clients
10.4 Marketing Channels Analysis
10.4.1 Marketing Channels
10.4.2 Infant and Child Multiple Vaccine Distributors and Sales Agents in Global
11 Conclusion
12 Appendix
12.1 Note
12.2 Examples of Clients
12.3 Disclaimer

List of Tables
Table 1. Key Players of Infant and Child Multiple Vaccine in Global Market
Table 2. Top Infant and Child Multiple Vaccine Players in Global Market, Ranking by Revenue (2022)
Table 3. Global Infant and Child Multiple Vaccine Revenue by Companies, (US$, Mn), 2018-2023
Table 4. Global Infant and Child Multiple Vaccine Revenue Share by Companies, 2018-2023
Table 5. Global Infant and Child Multiple Vaccine Sales by Companies, (M Doses), 2018-2023
Table 6. Global Infant and Child Multiple Vaccine Sales Share by Companies, 2018-2023
Table 7. Key Manufacturers Infant and Child Multiple Vaccine Price (2018-2023) & (US$/Dose)
Table 8. Global Manufacturers Infant and Child Multiple Vaccine Product Type
Table 9. List of Global Tier 1 Infant and Child Multiple Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Infant and Child Multiple Vaccine Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Global Infant and Child Multiple Vaccine Revenue (US$, Mn), 2018-2023
Table 13. By Type - Global Infant and Child Multiple Vaccine Revenue (US$, Mn), 2024-2029
Table 14. By Type - Global Infant and Child Multiple Vaccine Sales (M Doses), 2018-2023
Table 15. By Type - Global Infant and Child Multiple Vaccine Sales (M Doses), 2024-2029
Table 16. By Application – Global Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Table 17. By Application - Global Infant and Child Multiple Vaccine Revenue (US$, Mn), 2018-2023
Table 18. By Application - Global Infant and Child Multiple Vaccine Revenue (US$, Mn), 2024-2029
Table 19. By Application - Global Infant and Child Multiple Vaccine Sales (M Doses), 2018-2023
Table 20. By Application - Global Infant and Child Multiple Vaccine Sales (M Doses), 2024-2029
Table 21. By Region – Global Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2022 VS 2029
Table 22. By Region - Global Infant and Child Multiple Vaccine Revenue (US$, Mn), 2018-2023
Table 23. By Region - Global Infant and Child Multiple Vaccine Revenue (US$, Mn), 2024-2029
Table 24. By Region - Global Infant and Child Multiple Vaccine Sales (M Doses), 2018-2023
Table 25. By Region - Global Infant and Child Multiple Vaccine Sales (M Doses), 2024-2029
Table 26. By Country - North America Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 27. By Country - North America Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 28. By Country - North America Infant and Child Multiple Vaccine Sales, (M Doses), 2018-2023
Table 29. By Country - North America Infant and Child Multiple Vaccine Sales, (M Doses), 2024-2029
Table 30. By Country - Europe Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 31. By Country - Europe Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 32. By Country - Europe Infant and Child Multiple Vaccine Sales, (M Doses), 2018-2023
Table 33. By Country - Europe Infant and Child Multiple Vaccine Sales, (M Doses), 2024-2029
Table 34. By Region - Asia Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 35. By Region - Asia Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 36. By Region - Asia Infant and Child Multiple Vaccine Sales, (M Doses), 2018-2023
Table 37. By Region - Asia Infant and Child Multiple Vaccine Sales, (M Doses), 2024-2029
Table 38. By Country - South America Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 39. By Country - South America Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 40. By Country - South America Infant and Child Multiple Vaccine Sales, (M Doses), 2018-2023
Table 41. By Country - South America Infant and Child Multiple Vaccine Sales, (M Doses), 2024-2029
Table 42. By Country - Middle East & Africa Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2023
Table 43. By Country - Middle East & Africa Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2024-2029
Table 44. By Country - Middle East & Africa Infant and Child Multiple Vaccine Sales, (M Doses), 2018-2023
Table 45. By Country - Middle East & Africa Infant and Child Multiple Vaccine Sales, (M Doses), 2024-2029
Table 46. Sanofi Company Summary
Table 47. Sanofi Infant and Child Multiple Vaccine Product Offerings
Table 48. Sanofi Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 49. Sanofi Key News & Latest Developments
Table 50. GSK Company Summary
Table 51. GSK Infant and Child Multiple Vaccine Product Offerings
Table 52. GSK Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 53. GSK Key News & Latest Developments
Table 54. Mitsubishi Tanabe Pharma Company Summary
Table 55. Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Product Offerings
Table 56. Mitsubishi Tanabe Pharma Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 57. Mitsubishi Tanabe Pharma Key News & Latest Developments
Table 58. KM Biologics Company Summary
Table 59. KM Biologics Infant and Child Multiple Vaccine Product Offerings
Table 60. KM Biologics Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 61. KM Biologics Key News & Latest Developments
Table 62. Wuhan Institute of Biological Products Company Summary
Table 63. Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Product Offerings
Table 64. Wuhan Institute of Biological Products Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 65. Wuhan Institute of Biological Products Key News & Latest Developments
Table 66. Walvax Biotechnology Company Summary
Table 67. Walvax Biotechnology Infant and Child Multiple Vaccine Product Offerings
Table 68. Walvax Biotechnology Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 69. Walvax Biotechnology Key News & Latest Developments
Table 70. Chengdu Institute of Biological Products Company Summary
Table 71. Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Product Offerings
Table 72. Chengdu Institute of Biological Products Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 73. Chengdu Institute of Biological Products Key News & Latest Developments
Table 74. Minhai Biotechnology Company Summary
Table 75. Minhai Biotechnology Infant and Child Multiple Vaccine Product Offerings
Table 76. Minhai Biotechnology Infant and Child Multiple Vaccine Sales (M Doses), Revenue (US$, Mn) and Average Price (US$/Dose) (2018-2023)
Table 77. Minhai Biotechnology Key News & Latest Developments
Table 78. Infant and Child Multiple Vaccine Production Capacity (M Doses) of Key Manufacturers in Global Market, 2021-2023 (M Doses)
Table 79. Global Infant and Child Multiple Vaccine Capacity Market Share of Key Manufacturers, 2021-2023
Table 80. Global Infant and Child Multiple Vaccine Production by Region, 2018-2023 (M Doses)
Table 81. Global Infant and Child Multiple Vaccine Production by Region, 2024-2029 (M Doses)
Table 82. Infant and Child Multiple Vaccine Market Opportunities & Trends in Global Market
Table 83. Infant and Child Multiple Vaccine Market Drivers in Global Market
Table 84. Infant and Child Multiple Vaccine Market Restraints in Global Market
Table 85. Infant and Child Multiple Vaccine Raw Materials
Table 86. Infant and Child Multiple Vaccine Raw Materials Suppliers in Global Market
Table 87. Typical Infant and Child Multiple Vaccine Downstream
Table 88. Infant and Child Multiple Vaccine Downstream Clients in Global Market
Table 89. Infant and Child Multiple Vaccine Distributors and Sales Agents in Global Market
List of Figures
Figure 1. Infant and Child Multiple Vaccine Segment by Type in 2022
Figure 2. Infant and Child Multiple Vaccine Segment by Application in 2022
Figure 3. Global Infant and Child Multiple Vaccine Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Infant and Child Multiple Vaccine Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Infant and Child Multiple Vaccine Revenue, 2018-2029 (US$, Mn)
Figure 7. Infant and Child Multiple Vaccine Sales in Global Market: 2018-2029 (M Doses)
Figure 8. The Top 3 and 5 Players Market Share by Infant and Child Multiple Vaccine Revenue in 2022
Figure 9. By Type - Global Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 10. By Type - Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
Figure 11. By Type - Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
Figure 12. By Type - Global Infant and Child Multiple Vaccine Price (US$/Dose), 2018-2029
Figure 13. By Application - Global Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 14. By Application - Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
Figure 15. By Application - Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
Figure 16. By Application - Global Infant and Child Multiple Vaccine Price (US$/Dose), 2018-2029
Figure 17. By Region - Global Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2022 & 2029
Figure 18. By Region - Global Infant and Child Multiple Vaccine Revenue Market Share, 2018 VS 2022 VS 2029
Figure 19. By Region - Global Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
Figure 20. By Region - Global Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
Figure 21. By Country - North America Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
Figure 22. By Country - North America Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
Figure 23. US Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 24. Canada Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 25. Mexico Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 26. By Country - Europe Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
Figure 27. By Country - Europe Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
Figure 28. Germany Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 29. France Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 30. U.K. Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 31. Italy Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 32. Russia Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 33. Nordic Countries Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 34. Benelux Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 35. By Region - Asia Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
Figure 36. By Region - Asia Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
Figure 37. China Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 38. Japan Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 39. South Korea Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 40. Southeast Asia Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 41. India Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 42. By Country - South America Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
Figure 43. By Country - South America Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
Figure 44. Brazil Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 45. Argentina Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 46. By Country - Middle East & Africa Infant and Child Multiple Vaccine Revenue Market Share, 2018-2029
Figure 47. By Country - Middle East & Africa Infant and Child Multiple Vaccine Sales Market Share, 2018-2029
Figure 48. Turkey Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 49. Israel Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 50. Saudi Arabia Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 51. UAE Infant and Child Multiple Vaccine Revenue, (US$, Mn), 2018-2029
Figure 52. Global Infant and Child Multiple Vaccine Production Capacity (M Doses), 2018-2029
Figure 53. The Percentage of Production Infant and Child Multiple Vaccine by Region, 2022 VS 2029
Figure 54. Infant and Child Multiple Vaccine Industry Value Chain
Figure 55. Marketing Channels


世界の産業調査レポート販売サイトを運営しているマーケットリサーチセンターです。
• 英文レポート名:Infant and Child Multiple Vaccine Market, Global Outlook and Forecast 2023-2029
• 日本語訳:世界の乳幼児用混合ワクチン市場予測2023-2029:5種混合ワクチン、4種混合ワクチン、3種混合ワクチン、その他
• レポートコード:MRC2312MG02111お問い合わせ(見積依頼・ご注文・質問)